nodes	percent_of_prediction	percent_of_DWPC	metapath
Tolterodine—CYP3A4—bone cancer	0.935	1	CbGaD
Tolterodine—Fesoterodine—CYP3A4—bone cancer	0.00224	0.331	CrCbGaD
Tolterodine—Disopyramide—CYP3A4—bone cancer	0.001	0.148	CrCbGaD
Tolterodine—Phenprocoumon—CYP3A4—bone cancer	0.000982	0.145	CrCbGaD
Tolterodine—Brompheniramine—CYP3A4—bone cancer	0.000744	0.11	CrCbGaD
Tolterodine—Chlorphenamine—CYP3A4—bone cancer	0.000731	0.108	CrCbGaD
Tolterodine—Atomoxetine—CYP3A4—bone cancer	0.000614	0.0905	CrCbGaD
Tolterodine—Orphenadrine—CYP3A4—bone cancer	0.000469	0.0691	CrCbGaD
Tolterodine—Dementia—Methotrexate—bone cancer	0.0004	0.0432	CcSEcCtD
Tolterodine—Infection—Carboplatin—bone cancer	0.000361	0.039	CcSEcCtD
Tolterodine—Pain—Carboplatin—bone cancer	0.000311	0.0336	CcSEcCtD
Tolterodine—Anaphylactoid reaction—Cisplatin—bone cancer	0.000224	0.0242	CcSEcCtD
Tolterodine—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000224	0.00462	CbGpPWpGaD
Tolterodine—CHRM4—GPCR ligand binding—GRM4—bone cancer	0.000224	0.00461	CbGpPWpGaD
Tolterodine—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000222	0.00458	CbGpPWpGaD
Tolterodine—CYP2D6—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000221	0.00456	CbGpPWpGaD
Tolterodine—CYP2C9—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000219	0.00452	CbGpPWpGaD
Tolterodine—CHRM5—GPCR ligand binding—GRM4—bone cancer	0.000214	0.00441	CbGpPWpGaD
Tolterodine—CHRM5—Gastrin-CREB signalling pathway via PKC and MAPK—GNA11—bone cancer	0.000212	0.00437	CbGpPWpGaD
Tolterodine—CHRM1—Calcium Regulation in the Cardiac Cell—GNA11—bone cancer	0.0002	0.00413	CbGpPWpGaD
Tolterodine—CHRM3—Calcium Regulation in the Cardiac Cell—GNA11—bone cancer	0.0002	0.00412	CbGpPWpGaD
Tolterodine—CHRM2—Calcium Regulation in the Cardiac Cell—GNA11—bone cancer	0.000198	0.00408	CbGpPWpGaD
Tolterodine—CYP2C19—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000198	0.00407	CbGpPWpGaD
Tolterodine—CHRM4—GPCR ligand binding—GRM1—bone cancer	0.000194	0.004	CbGpPWpGaD
Tolterodine—CHRM5—GPCR ligand binding—GRM1—bone cancer	0.000186	0.00383	CbGpPWpGaD
Tolterodine—CYP2D6—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000182	0.00374	CbGpPWpGaD
Tolterodine—CYP2C9—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.00018	0.00371	CbGpPWpGaD
Tolterodine—CHRM1—G alpha (q) signalling events—GNA11—bone cancer	0.000167	0.00344	CbGpPWpGaD
Tolterodine—CHRM3—G alpha (q) signalling events—GNA11—bone cancer	0.000167	0.00343	CbGpPWpGaD
Tolterodine—CHRM1—Circadian rythm related genes—GNA11—bone cancer	0.000158	0.00325	CbGpPWpGaD
Tolterodine—CHRM1—Circadian rythm related genes—EZH2—bone cancer	0.000157	0.00323	CbGpPWpGaD
Tolterodine—CHRM1—GPCR ligand binding—GRM4—bone cancer	0.000151	0.00311	CbGpPWpGaD
Tolterodine—CHRM3—GPCR ligand binding—GRM4—bone cancer	0.00015	0.0031	CbGpPWpGaD
Tolterodine—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—GNA11—bone cancer	0.000149	0.00308	CbGpPWpGaD
Tolterodine—Influenza like illness—Epirubicin—bone cancer	0.000149	0.0161	CcSEcCtD
Tolterodine—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—GNA11—bone cancer	0.000149	0.00307	CbGpPWpGaD
Tolterodine—CHRM2—GPCR ligand binding—GRM4—bone cancer	0.000149	0.00307	CbGpPWpGaD
Tolterodine—CHRM4—Regulation of Actin Cytoskeleton—BRAF—bone cancer	0.000148	0.00304	CbGpPWpGaD
Tolterodine—Visual impairment—Cisplatin—bone cancer	0.000145	0.0156	CcSEcCtD
Tolterodine—Dry eye—Epirubicin—bone cancer	0.000142	0.0153	CcSEcCtD
Tolterodine—CHRM5—Regulation of Actin Cytoskeleton—BRAF—bone cancer	0.000141	0.00292	CbGpPWpGaD
Tolterodine—Flushing—Cisplatin—bone cancer	0.000139	0.015	CcSEcCtD
Tolterodine—Influenza like illness—Doxorubicin—bone cancer	0.000138	0.0149	CcSEcCtD
Tolterodine—CHRM4—GPCR ligand binding—SMO—bone cancer	0.000137	0.00282	CbGpPWpGaD
Tolterodine—Abnormal vision—Epirubicin—bone cancer	0.000134	0.0144	CcSEcCtD
Tolterodine—Dry eye—Doxorubicin—bone cancer	0.000131	0.0142	CcSEcCtD
Tolterodine—CHRM5—GPCR ligand binding—SMO—bone cancer	0.000131	0.0027	CbGpPWpGaD
Tolterodine—CHRM1—GPCR ligand binding—GRM1—bone cancer	0.000131	0.00269	CbGpPWpGaD
Tolterodine—CHRM3—GPCR ligand binding—GRM1—bone cancer	0.00013	0.00269	CbGpPWpGaD
Tolterodine—KCNH2—SIDS Susceptibility Pathways—JUN—bone cancer	0.00013	0.00267	CbGpPWpGaD
Tolterodine—CHRM2—GPCR ligand binding—GRM1—bone cancer	0.000129	0.00266	CbGpPWpGaD
Tolterodine—Flatulence—Cisplatin—bone cancer	0.000129	0.0139	CcSEcCtD
Tolterodine—CHRM4—GPCR downstream signaling—RGS1—bone cancer	0.000126	0.0026	CbGpPWpGaD
Tolterodine—CHRM4—GPCR downstream signaling—GRM4—bone cancer	0.000126	0.0026	CbGpPWpGaD
Tolterodine—CYP2C19—Arachidonic acid metabolism—PTGS2—bone cancer	0.000125	0.00257	CbGpPWpGaD
Tolterodine—Abnormal vision—Doxorubicin—bone cancer	0.000124	0.0134	CcSEcCtD
Tolterodine—Anaphylactoid reaction—Methotrexate—bone cancer	0.000123	0.0133	CcSEcCtD
Tolterodine—CHRM5—GPCR downstream signaling—RGS1—bone cancer	0.000121	0.00249	CbGpPWpGaD
Tolterodine—CHRM5—GPCR downstream signaling—GRM4—bone cancer	0.000121	0.00249	CbGpPWpGaD
Tolterodine—Anaphylactoid reaction—Epirubicin—bone cancer	0.000115	0.0124	CcSEcCtD
Tolterodine—CHRM4—Signaling by GPCR—GRM4—bone cancer	0.000115	0.00236	CbGpPWpGaD
Tolterodine—CHRM4—Signaling by GPCR—RGS1—bone cancer	0.000115	0.00236	CbGpPWpGaD
Tolterodine—CYP2C9—Arachidonic acid metabolism—PTGS2—bone cancer	0.000114	0.00235	CbGpPWpGaD
Tolterodine—KCNH2—Neuronal System—BRAF—bone cancer	0.000112	0.00231	CbGpPWpGaD
Tolterodine—Anxiety—Cisplatin—bone cancer	0.000111	0.012	CcSEcCtD
Tolterodine—CHRM5—Signaling by GPCR—RGS1—bone cancer	0.00011	0.00226	CbGpPWpGaD
Tolterodine—CHRM5—Signaling by GPCR—GRM4—bone cancer	0.00011	0.00226	CbGpPWpGaD
Tolterodine—CHRM4—GPCR downstream signaling—GRM1—bone cancer	0.00011	0.00226	CbGpPWpGaD
Tolterodine—Oedema—Cisplatin—bone cancer	0.000107	0.0115	CcSEcCtD
Tolterodine—Anaphylactic shock—Cisplatin—bone cancer	0.000107	0.0115	CcSEcCtD
Tolterodine—Anaphylactoid reaction—Doxorubicin—bone cancer	0.000107	0.0115	CcSEcCtD
Tolterodine—Infection—Cisplatin—bone cancer	0.000106	0.0114	CcSEcCtD
Tolterodine—CHRM5—GPCR downstream signaling—GRM1—bone cancer	0.000105	0.00216	CbGpPWpGaD
Tolterodine—CYP2C19—Biological oxidations—CYP3A4—bone cancer	0.000105	0.00216	CbGpPWpGaD
Tolterodine—Tachycardia—Cisplatin—bone cancer	0.000104	0.0112	CcSEcCtD
Tolterodine—CYP2C19—Metapathway biotransformation—CYP3A4—bone cancer	0.000103	0.00213	CbGpPWpGaD
Tolterodine—Dry skin—Epirubicin—bone cancer	0.000102	0.011	CcSEcCtD
Tolterodine—CHRM1—Regulation of Actin Cytoskeleton—BRAF—bone cancer	9.96e-05	0.00205	CbGpPWpGaD
Tolterodine—CHRM4—Signaling by GPCR—GRM1—bone cancer	9.95e-05	0.00205	CbGpPWpGaD
Tolterodine—CHRM3—Regulation of Actin Cytoskeleton—BRAF—bone cancer	9.93e-05	0.00205	CbGpPWpGaD
Tolterodine—CHRM2—Regulation of Actin Cytoskeleton—BRAF—bone cancer	9.83e-05	0.00203	CbGpPWpGaD
Tolterodine—Musculoskeletal discomfort—Cisplatin—bone cancer	9.72e-05	0.0105	CcSEcCtD
Tolterodine—CHRM3—Metabolism—NDUFA12—bone cancer	9.67e-05	0.00199	CbGpPWpGaD
Tolterodine—CYP2D6—Biological oxidations—CYP3A4—bone cancer	9.65e-05	0.00199	CbGpPWpGaD
Tolterodine—Dysuria—Methotrexate—bone cancer	9.63e-05	0.0104	CcSEcCtD
Tolterodine—Upper respiratory tract infection—Methotrexate—bone cancer	9.57e-05	0.0103	CcSEcCtD
Tolterodine—CYP2C9—Biological oxidations—CYP3A4—bone cancer	9.57e-05	0.00197	CbGpPWpGaD
Tolterodine—CHRM5—Signaling by GPCR—GRM1—bone cancer	9.53e-05	0.00196	CbGpPWpGaD
Tolterodine—CYP2D6—Metapathway biotransformation—CYP3A4—bone cancer	9.52e-05	0.00196	CbGpPWpGaD
Tolterodine—Dry skin—Doxorubicin—bone cancer	9.46e-05	0.0102	CcSEcCtD
Tolterodine—CYP2C9—Metapathway biotransformation—CYP3A4—bone cancer	9.44e-05	0.00194	CbGpPWpGaD
Tolterodine—KCNH2—Neuronal System—MDM2—bone cancer	9.38e-05	0.00193	CbGpPWpGaD
Tolterodine—Bronchitis—Epirubicin—bone cancer	9.27e-05	0.01	CcSEcCtD
Tolterodine—CHRM1—GPCR ligand binding—SMO—bone cancer	9.21e-05	0.0019	CbGpPWpGaD
Tolterodine—CHRM3—GPCR ligand binding—SMO—bone cancer	9.18e-05	0.00189	CbGpPWpGaD
Tolterodine—Pain—Cisplatin—bone cancer	9.13e-05	0.00984	CcSEcCtD
Tolterodine—CHRM2—GPCR ligand binding—SMO—bone cancer	9.09e-05	0.00187	CbGpPWpGaD
Tolterodine—Dysuria—Epirubicin—bone cancer	9.01e-05	0.00972	CcSEcCtD
Tolterodine—CYP2C19—Biological oxidations—GSTP1—bone cancer	8.97e-05	0.00185	CbGpPWpGaD
Tolterodine—Upper respiratory tract infection—Epirubicin—bone cancer	8.96e-05	0.00966	CcSEcCtD
Tolterodine—CHRM1—Circadian rythm related genes—CDK4—bone cancer	8.86e-05	0.00183	CbGpPWpGaD
Tolterodine—CYP2C19—Metapathway biotransformation—GSTP1—bone cancer	8.85e-05	0.00182	CbGpPWpGaD
Tolterodine—Feeling abnormal—Cisplatin—bone cancer	8.79e-05	0.00948	CcSEcCtD
Tolterodine—Weight increased—Epirubicin—bone cancer	8.77e-05	0.00946	CcSEcCtD
Tolterodine—Bronchitis—Doxorubicin—bone cancer	8.58e-05	0.00925	CcSEcCtD
Tolterodine—CHRM1—GPCR downstream signaling—GRM4—bone cancer	8.52e-05	0.00176	CbGpPWpGaD
Tolterodine—CHRM1—GPCR downstream signaling—RGS1—bone cancer	8.52e-05	0.00176	CbGpPWpGaD
Tolterodine—CHRM3—GPCR downstream signaling—GRM4—bone cancer	8.49e-05	0.00175	CbGpPWpGaD
Tolterodine—CHRM3—GPCR downstream signaling—RGS1—bone cancer	8.49e-05	0.00175	CbGpPWpGaD
Tolterodine—CHRM4—Regulation of Actin Cytoskeleton—EGFR—bone cancer	8.46e-05	0.00174	CbGpPWpGaD
Tolterodine—CHRM2—GPCR downstream signaling—GRM4—bone cancer	8.41e-05	0.00173	CbGpPWpGaD
Tolterodine—CHRM2—GPCR downstream signaling—RGS1—bone cancer	8.41e-05	0.00173	CbGpPWpGaD
Tolterodine—Urinary tract infection—Epirubicin—bone cancer	8.35e-05	0.00901	CcSEcCtD
Tolterodine—Dysuria—Doxorubicin—bone cancer	8.34e-05	0.00899	CcSEcCtD
Tolterodine—CYP3A4—Tryptophan metabolism—MDM2—bone cancer	8.33e-05	0.00172	CbGpPWpGaD
Tolterodine—Upper respiratory tract infection—Doxorubicin—bone cancer	8.29e-05	0.00894	CcSEcCtD
Tolterodine—CYP2D6—Biological oxidations—GSTP1—bone cancer	8.25e-05	0.0017	CbGpPWpGaD
Tolterodine—CYP2C9—Biological oxidations—GSTP1—bone cancer	8.18e-05	0.00169	CbGpPWpGaD
Tolterodine—CYP2D6—Metapathway biotransformation—GSTP1—bone cancer	8.14e-05	0.00168	CbGpPWpGaD
Tolterodine—Weight increased—Doxorubicin—bone cancer	8.12e-05	0.00875	CcSEcCtD
Tolterodine—CHRM5—Regulation of Actin Cytoskeleton—EGFR—bone cancer	8.1e-05	0.00167	CbGpPWpGaD
Tolterodine—CYP2C9—Metapathway biotransformation—GSTP1—bone cancer	8.07e-05	0.00166	CbGpPWpGaD
Tolterodine—Sinusitis—Epirubicin—bone cancer	8.06e-05	0.00869	CcSEcCtD
Tolterodine—CHRM3—Metabolism—NT5C3A—bone cancer	8.02e-05	0.00165	CbGpPWpGaD
Tolterodine—Visual impairment—Methotrexate—bone cancer	7.94e-05	0.00857	CcSEcCtD
Tolterodine—Hypersensitivity—Cisplatin—bone cancer	7.86e-05	0.00848	CcSEcCtD
Tolterodine—CHRM1—Signaling by GPCR—RGS1—bone cancer	7.74e-05	0.00159	CbGpPWpGaD
Tolterodine—CHRM1—Signaling by GPCR—GRM4—bone cancer	7.74e-05	0.00159	CbGpPWpGaD
Tolterodine—Urinary tract infection—Doxorubicin—bone cancer	7.73e-05	0.00834	CcSEcCtD
Tolterodine—CHRM3—Signaling by GPCR—GRM4—bone cancer	7.71e-05	0.00159	CbGpPWpGaD
Tolterodine—CHRM3—Signaling by GPCR—RGS1—bone cancer	7.71e-05	0.00159	CbGpPWpGaD
Tolterodine—Asthenia—Cisplatin—bone cancer	7.66e-05	0.00826	CcSEcCtD
Tolterodine—CHRM2—Signaling by GPCR—RGS1—bone cancer	7.64e-05	0.00157	CbGpPWpGaD
Tolterodine—CHRM2—Signaling by GPCR—GRM4—bone cancer	7.64e-05	0.00157	CbGpPWpGaD
Tolterodine—Oedema peripheral—Epirubicin—bone cancer	7.6e-05	0.0082	CcSEcCtD
Tolterodine—Sinusitis—Doxorubicin—bone cancer	7.46e-05	0.00805	CcSEcCtD
Tolterodine—Visual impairment—Epirubicin—bone cancer	7.43e-05	0.00802	CcSEcCtD
Tolterodine—CHRM1—GPCR downstream signaling—GRM1—bone cancer	7.39e-05	0.00152	CbGpPWpGaD
Tolterodine—CHRM3—GPCR downstream signaling—GRM1—bone cancer	7.36e-05	0.00152	CbGpPWpGaD
Tolterodine—Diarrhoea—Cisplatin—bone cancer	7.3e-05	0.00788	CcSEcCtD
Tolterodine—CHRM2—GPCR downstream signaling—GRM1—bone cancer	7.29e-05	0.0015	CbGpPWpGaD
Tolterodine—Flushing—Epirubicin—bone cancer	7.16e-05	0.00772	CcSEcCtD
Tolterodine—CHRM4—GPCR downstream signaling—GNA11—bone cancer	7.06e-05	0.00146	CbGpPWpGaD
Tolterodine—Oedema peripheral—Doxorubicin—bone cancer	7.03e-05	0.00758	CcSEcCtD
Tolterodine—CHRM4—Signaling by GPCR—SMO—bone cancer	7.01e-05	0.00144	CbGpPWpGaD
Tolterodine—CHRM2—SIDS Susceptibility Pathways—JUN—bone cancer	6.9e-05	0.00142	CbGpPWpGaD
Tolterodine—Visual impairment—Doxorubicin—bone cancer	6.88e-05	0.00742	CcSEcCtD
Tolterodine—CHRM4—Signaling Pathways—RGS1—bone cancer	6.78e-05	0.0014	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—GRM4—bone cancer	6.78e-05	0.0014	CbGpPWpGaD
Tolterodine—CHRM5—GPCR downstream signaling—GNA11—bone cancer	6.76e-05	0.00139	CbGpPWpGaD
Tolterodine—CHRM5—Signaling by GPCR—SMO—bone cancer	6.71e-05	0.00138	CbGpPWpGaD
Tolterodine—CHRM1—Signaling by GPCR—GRM1—bone cancer	6.71e-05	0.00138	CbGpPWpGaD
Tolterodine—CHRM3—Signaling by GPCR—GRM1—bone cancer	6.69e-05	0.00138	CbGpPWpGaD
Tolterodine—Flushing—Doxorubicin—bone cancer	6.62e-05	0.00714	CcSEcCtD
Tolterodine—CHRM2—Signaling by GPCR—GRM1—bone cancer	6.62e-05	0.00136	CbGpPWpGaD
Tolterodine—Flatulence—Epirubicin—bone cancer	6.62e-05	0.00714	CcSEcCtD
Tolterodine—CHRM5—Signaling Pathways—RGS1—bone cancer	6.49e-05	0.00134	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—GRM4—bone cancer	6.49e-05	0.00134	CbGpPWpGaD
Tolterodine—Vertigo—Methotrexate—bone cancer	6.45e-05	0.00695	CcSEcCtD
Tolterodine—CHRM4—Signaling by GPCR—GNA11—bone cancer	6.41e-05	0.00132	CbGpPWpGaD
Tolterodine—CHRM4—GPCR downstream signaling—IL3—bone cancer	6.4e-05	0.00132	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—NDUFA12—bone cancer	6.29e-05	0.0013	CbGpPWpGaD
Tolterodine—CHRM5—Signaling by GPCR—GNA11—bone cancer	6.14e-05	0.00127	CbGpPWpGaD
Tolterodine—CHRM5—GPCR downstream signaling—IL3—bone cancer	6.13e-05	0.00126	CbGpPWpGaD
Tolterodine—Flatulence—Doxorubicin—bone cancer	6.12e-05	0.0066	CcSEcCtD
Tolterodine—Arthralgia—Methotrexate—bone cancer	6.11e-05	0.00659	CcSEcCtD
Tolterodine—Chest pain—Methotrexate—bone cancer	6.11e-05	0.00659	CcSEcCtD
Tolterodine—CHRM5—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—bone cancer	6.04e-05	0.00125	CbGpPWpGaD
Tolterodine—Vertigo—Epirubicin—bone cancer	6.03e-05	0.00651	CcSEcCtD
Tolterodine—Palpitations—Epirubicin—bone cancer	5.93e-05	0.0064	CcSEcCtD
Tolterodine—Confusional state—Methotrexate—bone cancer	5.91e-05	0.00637	CcSEcCtD
Tolterodine—CHRM4—Signaling Pathways—GRM1—bone cancer	5.88e-05	0.00121	CbGpPWpGaD
Tolterodine—Anaphylactic shock—Methotrexate—bone cancer	5.86e-05	0.00632	CcSEcCtD
Tolterodine—Infection—Methotrexate—bone cancer	5.82e-05	0.00627	CcSEcCtD
Tolterodine—CHRM4—Signaling by GPCR—IL3—bone cancer	5.81e-05	0.0012	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—NDUFA12—bone cancer	5.78e-05	0.00119	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—NDUFA12—bone cancer	5.73e-05	0.00118	CbGpPWpGaD
Tolterodine—Arthralgia—Epirubicin—bone cancer	5.72e-05	0.00617	CcSEcCtD
Tolterodine—Chest pain—Epirubicin—bone cancer	5.72e-05	0.00617	CcSEcCtD
Tolterodine—CHRM1—Circadian rythm related genes—JUN—bone cancer	5.71e-05	0.00118	CbGpPWpGaD
Tolterodine—CHRM1—Regulation of Actin Cytoskeleton—EGFR—bone cancer	5.7e-05	0.00118	CbGpPWpGaD
Tolterodine—Anxiety—Epirubicin—bone cancer	5.7e-05	0.00614	CcSEcCtD
Tolterodine—CHRM3—Regulation of Actin Cytoskeleton—EGFR—bone cancer	5.69e-05	0.00117	CbGpPWpGaD
Tolterodine—CHRM2—Regulation of Actin Cytoskeleton—EGFR—bone cancer	5.63e-05	0.00116	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—GRM1—bone cancer	5.63e-05	0.00116	CbGpPWpGaD
Tolterodine—Dry mouth—Epirubicin—bone cancer	5.59e-05	0.00603	CcSEcCtD
Tolterodine—Vertigo—Doxorubicin—bone cancer	5.58e-05	0.00602	CcSEcCtD
Tolterodine—CHRM5—Signaling by GPCR—IL3—bone cancer	5.57e-05	0.00115	CbGpPWpGaD
Tolterodine—Confusional state—Epirubicin—bone cancer	5.53e-05	0.00596	CcSEcCtD
Tolterodine—Palpitations—Doxorubicin—bone cancer	5.49e-05	0.00592	CcSEcCtD
Tolterodine—Anaphylactic shock—Epirubicin—bone cancer	5.48e-05	0.00591	CcSEcCtD
Tolterodine—Oedema—Epirubicin—bone cancer	5.48e-05	0.00591	CcSEcCtD
Tolterodine—Infection—Epirubicin—bone cancer	5.45e-05	0.00587	CcSEcCtD
Tolterodine—CYP3A4—Biological oxidations—GSTP1—bone cancer	5.4e-05	0.00111	CbGpPWpGaD
Tolterodine—Tachycardia—Epirubicin—bone cancer	5.35e-05	0.00577	CcSEcCtD
Tolterodine—Musculoskeletal discomfort—Methotrexate—bone cancer	5.34e-05	0.00575	CcSEcCtD
Tolterodine—CYP3A4—Metapathway biotransformation—GSTP1—bone cancer	5.32e-05	0.0011	CbGpPWpGaD
Tolterodine—Chest pain—Doxorubicin—bone cancer	5.29e-05	0.00571	CcSEcCtD
Tolterodine—Arthralgia—Doxorubicin—bone cancer	5.29e-05	0.00571	CcSEcCtD
Tolterodine—Anxiety—Doxorubicin—bone cancer	5.27e-05	0.00569	CcSEcCtD
Tolterodine—CYP2C19—Metabolism—NT5C3A—bone cancer	5.21e-05	0.00107	CbGpPWpGaD
Tolterodine—Somnolence—Methotrexate—bone cancer	5.21e-05	0.00561	CcSEcCtD
Tolterodine—Dry mouth—Doxorubicin—bone cancer	5.17e-05	0.00558	CcSEcCtD
Tolterodine—Dyspepsia—Methotrexate—bone cancer	5.16e-05	0.00556	CcSEcCtD
Tolterodine—Confusional state—Doxorubicin—bone cancer	5.11e-05	0.00551	CcSEcCtD
Tolterodine—Oedema—Doxorubicin—bone cancer	5.07e-05	0.00547	CcSEcCtD
Tolterodine—Anaphylactic shock—Doxorubicin—bone cancer	5.07e-05	0.00547	CcSEcCtD
Tolterodine—Fatigue—Methotrexate—bone cancer	5.05e-05	0.00545	CcSEcCtD
Tolterodine—Infection—Doxorubicin—bone cancer	5.04e-05	0.00543	CcSEcCtD
Tolterodine—Pain—Methotrexate—bone cancer	5.01e-05	0.0054	CcSEcCtD
Tolterodine—Musculoskeletal discomfort—Epirubicin—bone cancer	4.99e-05	0.00539	CcSEcCtD
Tolterodine—Tachycardia—Doxorubicin—bone cancer	4.95e-05	0.00534	CcSEcCtD
Tolterodine—Somnolence—Epirubicin—bone cancer	4.87e-05	0.00525	CcSEcCtD
Tolterodine—Feeling abnormal—Methotrexate—bone cancer	4.83e-05	0.0052	CcSEcCtD
Tolterodine—Dyspepsia—Epirubicin—bone cancer	4.82e-05	0.0052	CcSEcCtD
Tolterodine—CYP2D6—Metabolism—NT5C3A—bone cancer	4.79e-05	0.000988	CbGpPWpGaD
Tolterodine—Gastrointestinal pain—Methotrexate—bone cancer	4.79e-05	0.00516	CcSEcCtD
Tolterodine—CHRM1—GPCR downstream signaling—GNA11—bone cancer	4.76e-05	0.000981	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—NT5C3A—bone cancer	4.75e-05	0.000979	CbGpPWpGaD
Tolterodine—CHRM3—GPCR downstream signaling—GNA11—bone cancer	4.75e-05	0.000978	CbGpPWpGaD
Tolterodine—CHRM1—Signaling by GPCR—SMO—bone cancer	4.73e-05	0.000974	CbGpPWpGaD
Tolterodine—Fatigue—Epirubicin—bone cancer	4.73e-05	0.0051	CcSEcCtD
Tolterodine—CHRM3—Signaling by GPCR—SMO—bone cancer	4.71e-05	0.000971	CbGpPWpGaD
Tolterodine—CHRM2—GPCR downstream signaling—GNA11—bone cancer	4.7e-05	0.000968	CbGpPWpGaD
Tolterodine—Pain—Epirubicin—bone cancer	4.69e-05	0.00505	CcSEcCtD
Tolterodine—Constipation—Epirubicin—bone cancer	4.69e-05	0.00505	CcSEcCtD
Tolterodine—CHRM2—Signaling by GPCR—SMO—bone cancer	4.67e-05	0.000962	CbGpPWpGaD
Tolterodine—Abdominal pain—Methotrexate—bone cancer	4.63e-05	0.00499	CcSEcCtD
Tolterodine—Musculoskeletal discomfort—Doxorubicin—bone cancer	4.62e-05	0.00498	CcSEcCtD
Tolterodine—CHRM1—Signaling Pathways—GRM4—bone cancer	4.57e-05	0.000942	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—RGS1—bone cancer	4.57e-05	0.000942	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—GRM4—bone cancer	4.56e-05	0.000939	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—RGS1—bone cancer	4.56e-05	0.000939	CbGpPWpGaD
Tolterodine—Feeling abnormal—Epirubicin—bone cancer	4.52e-05	0.00487	CcSEcCtD
Tolterodine—CHRM2—Signaling Pathways—RGS1—bone cancer	4.51e-05	0.00093	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—GRM4—bone cancer	4.51e-05	0.00093	CbGpPWpGaD
Tolterodine—Somnolence—Doxorubicin—bone cancer	4.51e-05	0.00486	CcSEcCtD
Tolterodine—Gastrointestinal pain—Epirubicin—bone cancer	4.48e-05	0.00483	CcSEcCtD
Tolterodine—Dyspepsia—Doxorubicin—bone cancer	4.46e-05	0.00481	CcSEcCtD
Tolterodine—Fatigue—Doxorubicin—bone cancer	4.37e-05	0.00472	CcSEcCtD
Tolterodine—Constipation—Doxorubicin—bone cancer	4.34e-05	0.00468	CcSEcCtD
Tolterodine—Pain—Doxorubicin—bone cancer	4.34e-05	0.00468	CcSEcCtD
Tolterodine—Abdominal pain—Epirubicin—bone cancer	4.33e-05	0.00467	CcSEcCtD
Tolterodine—CHRM1—Signaling by GPCR—GNA11—bone cancer	4.32e-05	0.000891	CbGpPWpGaD
Tolterodine—CHRM1—GPCR downstream signaling—IL3—bone cancer	4.32e-05	0.000889	CbGpPWpGaD
Tolterodine—Hypersensitivity—Methotrexate—bone cancer	4.31e-05	0.00465	CcSEcCtD
Tolterodine—CHRM3—Signaling by GPCR—GNA11—bone cancer	4.31e-05	0.000888	CbGpPWpGaD
Tolterodine—CHRM3—GPCR downstream signaling—IL3—bone cancer	4.3e-05	0.000887	CbGpPWpGaD
Tolterodine—CHRM2—Signaling by GPCR—GNA11—bone cancer	4.27e-05	0.000879	CbGpPWpGaD
Tolterodine—CHRM2—GPCR downstream signaling—IL3—bone cancer	4.26e-05	0.000878	CbGpPWpGaD
Tolterodine—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—bone cancer	4.25e-05	0.000877	CbGpPWpGaD
Tolterodine—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—bone cancer	4.24e-05	0.000874	CbGpPWpGaD
Tolterodine—Asthenia—Methotrexate—bone cancer	4.2e-05	0.00453	CcSEcCtD
Tolterodine—Feeling abnormal—Doxorubicin—bone cancer	4.18e-05	0.00451	CcSEcCtD
Tolterodine—Gastrointestinal pain—Doxorubicin—bone cancer	4.15e-05	0.00447	CcSEcCtD
Tolterodine—CHRM4—Signaling Pathways—SMO—bone cancer	4.14e-05	0.000853	CbGpPWpGaD
Tolterodine—Hypersensitivity—Epirubicin—bone cancer	4.04e-05	0.00435	CcSEcCtD
Tolterodine—Abdominal pain—Doxorubicin—bone cancer	4.01e-05	0.00432	CcSEcCtD
Tolterodine—Diarrhoea—Methotrexate—bone cancer	4.01e-05	0.00432	CcSEcCtD
Tolterodine—CHRM5—Signaling Pathways—SMO—bone cancer	3.97e-05	0.000817	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—GRM1—bone cancer	3.96e-05	0.000817	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—GRM1—bone cancer	3.95e-05	0.000814	CbGpPWpGaD
Tolterodine—Asthenia—Epirubicin—bone cancer	3.93e-05	0.00424	CcSEcCtD
Tolterodine—CHRM1—Signaling by GPCR—IL3—bone cancer	3.92e-05	0.000808	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—GRM1—bone cancer	3.91e-05	0.000806	CbGpPWpGaD
Tolterodine—CHRM3—Signaling by GPCR—IL3—bone cancer	3.91e-05	0.000805	CbGpPWpGaD
Tolterodine—Dizziness—Methotrexate—bone cancer	3.87e-05	0.00418	CcSEcCtD
Tolterodine—CHRM2—Signaling by GPCR—IL3—bone cancer	3.87e-05	0.000797	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—GNA11—bone cancer	3.79e-05	0.000781	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—NDUFA12—bone cancer	3.78e-05	0.000779	CbGpPWpGaD
Tolterodine—CHRM1—Circadian rythm related genes—TP53—bone cancer	3.77e-05	0.000777	CbGpPWpGaD
Tolterodine—Diarrhoea—Epirubicin—bone cancer	3.75e-05	0.00404	CcSEcCtD
Tolterodine—Hypersensitivity—Doxorubicin—bone cancer	3.74e-05	0.00403	CcSEcCtD
Tolterodine—Headache—Methotrexate—bone cancer	3.67e-05	0.00396	CcSEcCtD
Tolterodine—Asthenia—Doxorubicin—bone cancer	3.64e-05	0.00392	CcSEcCtD
Tolterodine—CHRM5—Signaling Pathways—GNA11—bone cancer	3.63e-05	0.000747	CbGpPWpGaD
Tolterodine—Dizziness—Epirubicin—bone cancer	3.62e-05	0.00391	CcSEcCtD
Tolterodine—CHRM4—Signaling Pathways—ATF1—bone cancer	3.52e-05	0.000726	CbGpPWpGaD
Tolterodine—CHRM3—Metabolism—ENO2—bone cancer	3.51e-05	0.000724	CbGpPWpGaD
Tolterodine—Diarrhoea—Doxorubicin—bone cancer	3.47e-05	0.00374	CcSEcCtD
Tolterodine—CHRM4—Signaling Pathways—IL3—bone cancer	3.43e-05	0.000708	CbGpPWpGaD
Tolterodine—Headache—Epirubicin—bone cancer	3.43e-05	0.0037	CcSEcCtD
Tolterodine—CHRM5—Signaling Pathways—ATF1—bone cancer	3.37e-05	0.000695	CbGpPWpGaD
Tolterodine—Dizziness—Doxorubicin—bone cancer	3.35e-05	0.00362	CcSEcCtD
Tolterodine—CHRM5—Signaling Pathways—IL3—bone cancer	3.29e-05	0.000678	CbGpPWpGaD
Tolterodine—CHRM3—Metabolism—DHFR—bone cancer	3.26e-05	0.000671	CbGpPWpGaD
Tolterodine—Headache—Doxorubicin—bone cancer	3.18e-05	0.00343	CcSEcCtD
Tolterodine—CYP3A4—Metabolism—NT5C3A—bone cancer	3.13e-05	0.000646	CbGpPWpGaD
Tolterodine—CHRM3—Metabolism—GNA11—bone cancer	3.04e-05	0.000627	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—TGFBR2—bone cancer	2.94e-05	0.000605	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—TGFBR2—bone cancer	2.81e-05	0.00058	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—SMO—bone cancer	2.79e-05	0.000575	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—SMO—bone cancer	2.78e-05	0.000574	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—IGF1R—bone cancer	2.76e-05	0.000569	CbGpPWpGaD
Tolterodine—CHRM3—Metabolism—CYP3A4—bone cancer	2.76e-05	0.000569	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—SMO—bone cancer	2.76e-05	0.000568	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—IGF1R—bone cancer	2.65e-05	0.000545	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—GNA11—bone cancer	2.55e-05	0.000526	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—GNA11—bone cancer	2.55e-05	0.000525	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—GNA11—bone cancer	2.52e-05	0.00052	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—ATF1—bone cancer	2.37e-05	0.000489	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—ATF1—bone cancer	2.37e-05	0.000488	CbGpPWpGaD
Tolterodine—CHRM3—Metabolism—GSTP1—bone cancer	2.36e-05	0.000486	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—ATF1—bone cancer	2.34e-05	0.000483	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—IL3—bone cancer	2.32e-05	0.000477	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—IL3—bone cancer	2.31e-05	0.000476	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—IL3—bone cancer	2.29e-05	0.000471	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—ENO2—bone cancer	2.28e-05	0.00047	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—DHFR—bone cancer	2.12e-05	0.000436	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—ENO2—bone cancer	2.1e-05	0.000433	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—ENO2—bone cancer	2.08e-05	0.000429	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—KIT—bone cancer	2e-05	0.000413	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—TGFBR2—bone cancer	1.98e-05	0.000408	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—GNA11—bone cancer	1.98e-05	0.000408	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—TGFBR2—bone cancer	1.97e-05	0.000407	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—TGFBR2—bone cancer	1.95e-05	0.000403	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—DHFR—bone cancer	1.95e-05	0.000401	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—DHFR—bone cancer	1.93e-05	0.000398	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—KIT—bone cancer	1.92e-05	0.000395	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—BRAF—bone cancer	1.88e-05	0.000388	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—IGF1R—bone cancer	1.86e-05	0.000384	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—IGF1R—bone cancer	1.86e-05	0.000383	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—IGF1R—bone cancer	1.84e-05	0.000379	CbGpPWpGaD
Tolterodine—CHRM4—Signaling by GPCR—EGFR—bone cancer	1.83e-05	0.000376	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—GNA11—bone cancer	1.82e-05	0.000375	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—GNA11—bone cancer	1.8e-05	0.000372	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—BRAF—bone cancer	1.8e-05	0.000372	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—CYP3A4—bone cancer	1.79e-05	0.00037	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.79e-05	0.000368	CbGpPWpGaD
Tolterodine—CHRM5—Signaling by GPCR—EGFR—bone cancer	1.75e-05	0.00036	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—CYP3A4—bone cancer	1.65e-05	0.00034	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—CYP3A4—bone cancer	1.64e-05	0.000337	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.63e-05	0.000335	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—MDM2—bone cancer	1.58e-05	0.000325	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—GSTP1—bone cancer	1.53e-05	0.000316	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—MDM2—bone cancer	1.51e-05	0.000311	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—GSTP1—bone cancer	1.41e-05	0.000291	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—GSTP1—bone cancer	1.4e-05	0.000288	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—ENO2—bone cancer	1.37e-05	0.000283	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—JUN—bone cancer	1.37e-05	0.000283	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—KIT—bone cancer	1.35e-05	0.000278	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—KIT—bone cancer	1.35e-05	0.000278	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—MMP9—bone cancer	1.33e-05	0.000275	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—KIT—bone cancer	1.33e-05	0.000275	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—JUN—bone cancer	1.31e-05	0.000271	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—MMP9—bone cancer	1.28e-05	0.000263	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—DHFR—bone cancer	1.27e-05	0.000262	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—BRAF—bone cancer	1.27e-05	0.000262	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—BRAF—bone cancer	1.27e-05	0.000261	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—BRAF—bone cancer	1.25e-05	0.000258	CbGpPWpGaD
Tolterodine—CHRM1—Signaling by GPCR—EGFR—bone cancer	1.23e-05	0.000254	CbGpPWpGaD
Tolterodine—CHRM3—Signaling by GPCR—EGFR—bone cancer	1.23e-05	0.000253	CbGpPWpGaD
Tolterodine—CHRM3—Metabolism—PTGS2—bone cancer	1.22e-05	0.000252	CbGpPWpGaD
Tolterodine—CHRM2—Signaling by GPCR—EGFR—bone cancer	1.22e-05	0.00025	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—GNA11—bone cancer	1.19e-05	0.000245	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—EGFR—bone cancer	1.08e-05	0.000222	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—MDM2—bone cancer	1.06e-05	0.000219	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—MDM2—bone cancer	1.06e-05	0.000219	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—MDM2—bone cancer	1.05e-05	0.000216	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—EGFR—bone cancer	1.03e-05	0.000213	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—JUN—bone cancer	9.25e-06	0.000191	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—GSTP1—bone cancer	9.23e-06	0.00019	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—JUN—bone cancer	9.22e-06	0.00019	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—JUN—bone cancer	9.13e-06	0.000188	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—TP53—bone cancer	9.06e-06	0.000187	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—MMP9—bone cancer	9e-06	0.000185	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—MMP9—bone cancer	8.97e-06	0.000185	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—MMP9—bone cancer	8.88e-06	0.000183	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—TP53—bone cancer	8.67e-06	0.000179	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—PTGS2—bone cancer	7.95e-06	0.000164	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—PTGS2—bone cancer	7.31e-06	0.000151	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—EGFR—bone cancer	7.27e-06	0.00015	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—PTGS2—bone cancer	7.25e-06	0.000149	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—EGFR—bone cancer	7.25e-06	0.000149	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—EGFR—bone cancer	7.18e-06	0.000148	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—TP53—bone cancer	6.11e-06	0.000126	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—TP53—bone cancer	6.09e-06	0.000125	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—TP53—bone cancer	6.03e-06	0.000124	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—PTGS2—bone cancer	4.78e-06	9.85e-05	CbGpPWpGaD
